Allogeneic transplantation versus chemotherapy as postremission therapy
for acute myeloid leukemia: A prospective matched pairs analysis.
Other Molecular Markers and an Integrated Approach to the Choice of Postremission Therapy
Even in the era of molecular markers in AML, standard prognostic factors (patient-related and disease-related) still play an important role in an integrated approach to the choice of postremission therapy .
showed that the FLT3-ITD mRNA level has a high prognostic impact in NPM1-mutated AML-NK, and that it contributes to relapse risk stratification and might help to guide postremission therapy
in NPM1-mutated AML (29).
(23) Marcucci et al (10) reported that 50% of patients with CBF AML have long-term survival when repetitive cycles of high-dose cytarabine are used as postremission therapy
. For both subtypes of CBF AML, patients have a high complete remission rate with long-term, disease-free survival when treated with high-dose cytarabine in the consolidation phase.
A long-term follow-up of the Group for Research on Adult Acute Lymphoblastic Leukemia Philadelphia- positive-2003 trial described the outcomes of 45 patients whose postremission therapy
was partly decided by MRD results.[sup] Imatinib doses of 600-800 mg daily were given with consolidation chemotherapy.
This retrospective study was performed to explore the predictive factors and the role of auto-HSCT in the postremission therapy
for ALL patients.